David Mott

Président chez ARDELYX, INC. Fortune : 21 M $ au 31/05/2026

Profil

Mr. David M.
Mott is an Independent Director at Novavax, Inc., a Chairman at Ardelyx, Inc. and a Chairman at Cydan LLC.
He is on the Board of Directors at Novavax, Inc., Biotechnology Innovation Organization, NEA 14 GP Ltd. and XTuit Pharmaceuticals, Inc. Mr. Mott was previously employed as a Chairman by Imara, Inc., an Independent Director by Clementia Pharmaceuticals, Inc., an Independent Non-Executive Director by Nightstar Therapeutics Plc, a Chairman by Adaptimmune Ltd., a Chairman by Adaptimmune Therapeutics Plc, a Chairman by Mersana Therapeutics, Inc., a Chairman-Supervisory Board by Prosensa Holding NV, a Chairman by Epizyme, Inc., a General Partner by NEA Management Co. LLC, a General Partner by New Enterprise Associates LLC, a Non-Executive Director by Shire Plc, an Executive Vice President by AstraZeneca PLC, a President by MedImmune Ventures, Inc., a Vice Chairman, President & Chief Executive Officer by MedImmune LLC, a President & Chief Executive Officer by MedImmune Ltd., a Vice President-Health Care Investment Banking by Smith Barney Harris Upham & Co., Inc., a Chairman by Complexa, Inc., a Chairman by Conceptis Technologies, Inc., a Chairman by Cydan II, Inc., a VP-Health Care Investment Banking Group by Harris Upham & Co, Inc., a Chairman by Sagimet Biosciences, Inc., a Member-Governing Board by St. Albans School, a Trustee by St. James' School, a Chairman by Vtesse, Inc., and a Chairman by Zyngenia, Inc. He also served on the board at Polyneuron Pharmaceuticals AG, Tiburio Therapeutics, Inc., Omthera Pharmaceuticals, Inc., Tesaro, Inc., Ambit Biosciences Corp., Biohealth Innovation, Inc., Edimer Pharmaceuticals, Inc., Melinta Subsidiary Corp., NightstaRx Ltd., Shire Pharmaceuticals, Inc., Shire Plc /Old/, Zosano Pharma Corp.
and ZP Opco, Inc. He received his undergraduate degree from Dartmouth College.

Détentions connues dans des sociétés publiques

Société	Date	Nombre d'actions	Valorisation	Date de valorisation
ARDELYX, INC. 1,36 %	16/06/2026	3 349 655 ( 1,36 % )	20 M $	31/05/2026
NOVAVAX, INC. 0,05 %	23/04/2026	79 770 ( 0,05 % )	875 077 $	31/05/2026
ADAPTIMMUNE THERAPEUTICS PLC -.--%	11/04/2025	0 ( -.--% )	- $	31/05/2026
MERSANA THERAPEUTICS, INC. -.--%	06/01/2026	0 ( -.--% )	- $	31/12/2025

Postes actifs de David Mott

Sociétés	Poste	Début
ARDELYX, INC.	Président	01/03/2014
NOVAVAX, INC.	Directeur/Membre du Conseil	16/06/2020
Cydan LLC	Président	-
NEA 14 GP Ltd.	Directeur/Membre du Conseil	-
XTuit Pharmaceuticals, Inc.	Directeur/Membre du Conseil	-
Biotechnology Innovation Organization	Directeur/Membre du Conseil	-

Anciens postes connus de David Mott

Sociétés	Poste	Fin
MERSANA THERAPEUTICS	Directeur Général	02/03/2015
ADAPTIMMUNE THERAPEUTICS PLC	Président	14/11/2025
IMARA	Président	01/02/2023
░░░░░░░░ ░░░░	░░░░░░░░░░	░░░░░░░░░░
░░░ ░░░░░░░░░░ ░░░ ░░░	░░░░░░░ ░░░░░░ ░░░░░░░░	░░░░░░░░░░